The carton has a barcode. The blister pack has a batch number. And yet the tablet, the thing a person actually swallows, can walk away from both. This is the small, maddening gap TruTag Technologies set out to close. Its answer is to give the object itself a covert identity: a microscopic piece of engineered silica whose optical signature can be read with a suitable phone app or dedicated scanner.
The story in four bites
- TruTag makes silica microtags that can be placed directly in tablet coatings and other products.
- Drugmakers, coating suppliers and brand owners use its approach to check authenticity closer to the item itself.
- WuXi, Colorcon and PwC Australia helped test and demonstrate parts of the idea; broad commercial adoption is a separate question.
- Its newer SiCare Bio unit uses related silica manufacturing for drug delivery.
The proposition sounds like a magic trick until you look at the mechanics. TruTags are roughly 50 to 100 microns across. Their engineered pores create a distinctive optical response. That response is the code. There is no printed number on the tablet and no electronic chip inside it. The particle is small enough to disappear into a coating, yet structured enough for optics and software to recognize.
The wrapper’s awkward secret
Modern supply chains already have plenty of identifiers. Serial numbers, package barcodes and tamper features can do valuable work. They do not, by themselves, tell you much about a loose tablet. A genuine box can be emptied. A pill can be separated from its original blister. A convincing label can be attached to the wrong contents. TruTag’s distinction is location: its mark can ride on the dose.
That matters to a pharmaceutical manufacturer investigating a suspicious return, a distributor checking diverted stock or, potentially, a patient with a phone. The tag could connect a scan to information such as lot, origin or expiry, depending on what a manufacturer chooses to record and expose. It does not identify chemical composition by itself. It verifies a physical signature against a system, so the system’s enrollment, records and controls still matter.
The company came out of a research project associated with Honolulu incubator Skai Ventures. Peter Wong recalled joining the effort in 2010 when it was still a project backed by a US military grant. Wong, optical scientist Michael O’Neill and Skai Ventures founder Hank Wuh became the founding names attached to the company, established in 2011. It is an unusual founding mix: materials science, optics, medicine and the less photogenic art of getting technology into a market.
A laboratory result meets a coating line
An edible code is interesting. A code that survives pharmaceutical manufacturing is a business. In 2015, TruTag and WuXi PharmaTech reported successful joint tests of on-dose authentication, then planned further testing on additional active ingredients. The work moved beyond a clever particle toward questions that drugmakers actually ask: Can it be applied? Can it be detected? What happens to dissolution and stability?
Colorcon, a supplier of tablet coatings, became the crucial industrial companion. The companies announced a development agreement in 2019 to incorporate TruTag’s silica markers in familiar film coatings. A coating supplier brings a route into existing manufacturing practice. TruTag brought the invisible signature. Neither contribution alone would be the same proposition.
“These systems are still reliant on ensuring a secure link or crypto anchor between the physical and digital world.”Trent Lund, PwC Australia, speaking about digital supply-chain records in 2018
Later that year, TruTag, Colorcon and PwC Australia ran a supply-chain simulation using a coated placebo tablet. A phone application read the tag and connected the physical tablet to a digital ledger. It was a demonstration, not proof that tagged medicines had suddenly filled pharmacy shelves. What it did show was the logic of the system: a ledger can remember a product only if the product has a dependable way to introduce itself.
The business is bigger than the particle
A customer is buying more than dust-sized silica. TruTag’s platform joins tag fabrication, application, optical reading, software and the records that make a successful scan useful. It sells to organizations with products worth protecting: pharmaceutical companies and suppliers first, but also food producers, cosmetics companies, apparel brands and makers of industrial goods. Battery developer Cuberg announced in 2020 that it would use TruTag markers to verify its products. Its 2018 alliance with PwC Australia put edible tags into a food-trust effort; a 2023 arrangement with glassmaker Gerresheimer aimed similar verification at beauty products.
That breadth is both opportunity and homework. A marker for a pill coating must fit one production process; a marker for a cosmetics bottle meets another. Phone reading also has to work in the real conditions where people scan, not only under laboratory lights. TruTag has built dedicated hyperspectral readers, and in 2018 it spun its imaging work into HinaLea Imaging. The company’s edge lies in making the physical mark and the optical detection work together.
What does it cost? TruTag does not publish a price list. A buyer would need to price particles, application or coating integration, scanners or app deployment, record-system work and validation. The 2019 demonstration was a useful technical proof, but public materials do not establish the total cost of a commercial rollout.
The first weakness this business addresses is plain: a package-level identifier loses authority over a pill once the two part company. The company’s own course then widened. Phone-based authentication reduced dependence on specialist hardware in some settings; the 2019 demonstration showed how the tag could connect to a digital record. Those shifts did not make packaging obsolete. They gave manufacturers another layer when packaging alone cannot answer the question.
From code carrier to drug carrier
In October 2024, TruTag announced SiCare Bio, a new business unit based on its ability to make precise nanoporous silica. This time the pores are not merely an identity mechanism. The proposed applications are targeted drug delivery with nanoparticles and extended release with microparticles. TruTag said the unit was already working with three pharmaceutical companies. That is a statement about development activity, not an approved therapy.
A 2023 supply partnership with Spinnaker Biosciences makes the turn concrete. Spinnaker is developing a treatment for age-related macular degeneration in which silica particles carry a drug and release it over months. The route from an edible security marker to a therapeutic carrier is less strange than it first appears: both depend on controlling the architecture of tiny pores with repeatable manufacturing.
There is a useful lesson here for anyone building a product-identity system. Start with the moment the object can become detached from its paperwork. Put the identity where that separation cannot remove it. Then test the entire chain - application, reading and record lookup - with the partners who already touch the product. TruTag’s partnerships show that the unglamorous middle, from film coating to data entry, is where a persuasive demonstration becomes a real deployment.
Its public record is strongest on prototypes, partnerships and technical demonstrations. The most interesting question now is how often a dose in ordinary commerce carries that tiny alibi. Until then, the company has made one point rather elegantly: a medicine should not have to rely entirely on its box to say what it is.